Presentation is loading. Please wait.

Presentation is loading. Please wait.

Forest plot of CIMT progression rate for atorvastatin treatment versus placebo for 3 years by baseline serum 25-hydroxyvitamin D status. Forest plot of.

Published byAshlyn Long Modified over 5 years ago

Similar presentations

Presentation on theme: "Forest plot of CIMT progression rate for atorvastatin treatment versus placebo for 3 years by baseline serum 25-hydroxyvitamin D status. Forest plot of."— Presentation transcript:

1 Forest plot of CIMT progression rate for atorvastatin treatment versus placebo for 3 years by baseline serum 25-hydroxyvitamin D status. Forest plot of CIMT progression rate for atorvastatin treatment versus placebo for 3 years by baseline serum 25-hydroxyvitamin D status. Multivariable mixed effects longitudinal modelling adjusted for lupus duration, female gender, systolic blood pressure, pubertal level, LDL cholesterol and hsCRP. VitD, serum 25-hydroxyvitamin D status, ng/mL; CIMT, carotid intima medial thickness, in mm; hsCRP, high-sensitivity C reactive protein; LDL, low-density lipoprotein. p Values for the interaction effect are listed in parentheses on the y-axis. Angela Byun Robinson et al. Lupus Sci Med 2014;1:e000037 ©2014 by Lupus Foundation of America

Download ppt "Forest plot of CIMT progression rate for atorvastatin treatment versus placebo for 3 years by baseline serum 25-hydroxyvitamin D status. Forest plot of."

Similar presentations

Slide Source: www.lipidsonline.org Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.

Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.
Philip J. Barter, et al. Circulation 2011;124:555-562.

Philip J. Barter, et al. Circulation 2011;124:
Slide Source: Lipids Online Slide Library www.lipidsonline.org LDL Cholesterol, mg/dL Years of Follow-up Ridker PM et al. N Engl J Med 2002;347:1557–1565.

Slide Source: Lipids Online Slide Library LDL Cholesterol, mg/dL Years of Follow-up Ridker PM et al. N Engl J Med 2002;347:1557–1565.
Ridker PM, et al. Lancet 2009;373:1175-82. Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.
Copyright © 2014 American Medical Association. All rights reserved.

Copyright © 2014 American Medical Association. All rights reserved.
Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.

Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.
Baseline Characteristics of the Patients Part I

Baseline Characteristics of the Patients Part I
Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.
HbA1c 1245_0025final--01-1502--study-report-body. Table 15.2.4.3.1.3: 1 HbA1c (%) change from baseline MMRM results over time − FAS (OC−AD) 12 28 40 52.

HbA1c 1245_0025final study-report-body. Table : 1 HbA1c (%) change from baseline MMRM results over time − FAS (OC−AD)
Association of blood lipids with AF

Association of blood lipids with AF
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.

Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.
Effect of evolocumab on lipoprotein particles

Effect of evolocumab on lipoprotein particles
Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.
Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.

Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.
Impact of Vitamin D Status and Obesity on C-Reactive Protein in Kidney-Transplant Patients  Bettina Ewers, MSc, Ane Gasbjerg, MSc, Bo Zerahn, MD, Peter.

Impact of Vitamin D Status and Obesity on C-Reactive Protein in Kidney-Transplant Patients  Bettina Ewers, MSc, Ane Gasbjerg, MSc, Bo Zerahn, MD, Peter.
Fellström BC, et al. N Engl J Med 2009;360:1455-7

Fellström BC, et al. N Engl J Med 2009;360:1455-7
Joshua A. Bell et al. JACC 2018;72:

Joshua A. Bell et al. JACC 2018;72:
Description of studies for pooled analyses

Description of studies for pooled analyses
End point Net change with soy supplements vs control (95% CI) p

End point Net change with soy supplements vs control (95% CI) p

Similar presentations

Ads by Google